Risk comparison of osteonecrosis of the jaw in osteoporotic patients treated with bisphosphonates vs. denosumab: a multi-institutional retrospective cohort study in Taiwan

被引:13
作者
Liu, Fang-Chun [1 ]
Luk, Kwing-Chi [1 ]
Chen, Yung-Chih [2 ,3 ]
机构
[1] Chang Gung Mem Hosp, Dept Dent, Keelung, Taiwan
[2] Chang Gung Mem Hosp, Dept Internal Med, Div Gen Internal Med, Keelung, Taiwan
[3] Chang Gung Univ, Coll Med, Taoyuan, Taiwan
关键词
Osteoporosis; Bone necrosis of jaw; Denosumab; Bisphosphonates; MEDICATION-RELATED OSTEONECROSIS; SURGEONS POSITION PAPER; ZOLEDRONIC ACID; AMERICAN ASSOCIATION; POSTMENOPAUSAL WOMEN; CANCER-PATIENTS; MANAGEMENT; ALENDRONATE; PREVENTION; TURNOVER;
D O I
10.1007/s00198-023-06818-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In this multi-institutional retrospective cohort study, we compared the long-term risk of osteonecrosis of the jaw following the use of denosumab vs. bisphosphonates in osteoporotic patients. After 2-year use, the likelihood of osteonecrosis of the jaw is lower with denosumab compared to bisphosphonates, and the difference increases with time.PurposeTo compare the long-term risk of osteonecrosis of the jaw (ONJ) between osteoporotic patients treated with bisphosphonates (BPs) and denosumab.MethodsThis multi-institutional retrospective cohort study included patients aged > 40 years with osteoporosis between January 2010 and December 2018. Patients who met the eligibility criteria were divided into BPs and denosumab groups by propensity score matching (PSM). The risk of ONJ of denosumab vs. BPs was estimated using a Cox proportional hazards model and was described by the cumulative incidence rate using the Kaplan-Meier method.ResultsA total of 84,102 patients with osteoporosis were enrolled, among whom, 8962 were eligible for inclusion based on their first-line drug use (denosumab, n = 3,823; BPs, n = 5,139). Following PCM matching (1:1), the BPs and denosumab groups included 3665 patients each. The incidence density of ONJ in the denosumab and BPs matching groups was 1.47 vs. 2.49 events (per 1000 person-years), respectively. The hazard ratio of ONJ in the denosumab vs. BPs group was estimated as 0.581 (95% confidence interval: 0.33-1.04, p = 0.07). The cumulative incidence rates of ONJ in both groups were similar for the first and second years of drug use (p = 0.062), but significantly different from the third year onwards (p = 0.022). The severity of ONJ was not significantly different between the two groups.ConclusionIn osteoporotic patients, after 2 years of use, the likelihood of ONJ being induced by denosumab is lower than that of BPs, and the difference increases with time.
引用
收藏
页码:1729 / 1737
页数:9
相关论文
共 59 条
[2]   Osteonecrosis of the Jaw in a Patient on Denosumab [J].
Aghaloo, Tara L. ;
Felsenfeld, Alan L. ;
Tetradis, Sotirios .
JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2010, 68 (05) :959-963
[3]   Persistent bone resorption lacunae on necrotic bone distinguish bisphosphonate-related osteonecrosis of jaw from denosumab-related osteonecrosis [J].
Aoki, Kazumitsu ;
Matsunaga, Satoru ;
Ito, Shinichirou ;
Shibahara, Takahiko ;
Nomura, Takeshi ;
Matsuzaki, Hideo ;
Abe, Shinichi ;
Yamaguchi, Akira .
JOURNAL OF BONE AND MINERAL METABOLISM, 2021, 39 (05) :737-747
[4]  
Bansal Hitesh, 2022, Natl J Maxillofac Surg, V13, P5, DOI 10.4103/njms.NJMS_236_20
[5]   Risk Factors for Osteonecrosis of the Jaws: a Case-Control Study from the CONDOR Dental PBRN [J].
Barasch, A. ;
Cunha-Cruz, J. ;
Curro, F. A. ;
Hujoel, P. ;
Sung, A. H. ;
Vena, D. ;
Voinea-Griffin, A. E. .
JOURNAL OF DENTAL RESEARCH, 2011, 90 (04) :439-444
[6]  
Benjamin Biju, 2016, Osteoporos Sarcopenia, V2, P77, DOI 10.1016/j.afos.2016.03.003
[7]   The Effect of 6 Versus 9 Years of Zoledronic Acid Treatment in Osteoporosis: A Randomized Second Extension to the HORIZON-Pivotal Fracture Trial (PFT) [J].
Black, Dennis M. ;
Reid, Ian R. ;
Cauley, Jane A. ;
Cosman, Felicia ;
Leung, Ping Chung ;
Lakatos, Peter ;
Lippuner, Kurt ;
Cummings, Steven R. ;
Hue, Trisha F. ;
Mukhopadhyay, Amitava ;
Tan, Monique ;
Aftring, R. Paul ;
Eastell, Richard .
JOURNAL OF BONE AND MINERAL RESEARCH, 2015, 30 (05) :934-944
[8]   10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension [J].
Bone, Henry G. ;
Wagman, Rachel B. ;
Brandi, Maria L. ;
Brown, Jacques P. ;
Chapurlat, Roland ;
Cummings, Steven R. ;
Czerwinski, Edward ;
Fahrleitner-Pammer, Astrid ;
Kendler, David L. ;
Lippuner, Kurt ;
Reginster, Jean-Yves ;
Roux, Christian ;
Malouf, Jorge ;
Bradley, Michelle N. ;
Daizadeh, Nadia S. ;
Wang, Andrea ;
Dakin, Paula ;
Pannacciulli, Nicola ;
Dempster, David W. ;
Papapoulos, Socrates .
LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (07) :513-523
[9]   The Effect of Three or Six Years of Denosumab Exposure in Women With Postmenopausal Osteoporosis: Results From the FREEDOM Extension [J].
Bone, Henry G. ;
Chapurlat, Roland ;
Brandi, Maria-Luisa ;
Brown, Jacques P. ;
Czerwinski, Edward ;
Krieg, Marc-Antoine ;
Mellstrom, Dan ;
Radominski, Sebastiao C. ;
Reginster, Jean-Yves ;
Resch, Heinrich ;
Roman Ivorra, Jose A. ;
Roux, Christian ;
Vittinghoff, Eric ;
Daizadeh, Nadia S. ;
Wang, Andrea ;
Bradley, Michelle N. ;
Franchimont, Nathalie ;
Geller, Michelle L. ;
Wagman, Rachel B. ;
Cummings, Steven R. ;
Papapoulos, Socrates .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2013, 98 (11) :4483-4492
[10]   AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS-2016 EXECUTIVE SUMMARY [J].
Camacho, Pauline M. ;
Petak, Steven M. ;
Binkley, Neil ;
Clarke, Bart L. ;
Harris, Steven T. ;
Hurley, Daniel L. ;
Kleerekoper, Michael ;
Lewiecki, E. Michael ;
Miller, Paul D. ;
Narula, Harmeet S. ;
Pessah-Pollack, Rachel ;
Tangpricha, Vin ;
Wimalawansa, Sunil J. ;
Watts, Nelson B. .
ENDOCRINE PRACTICE, 2016, 22 (09) :1111-1118